



Hemlibra[®] (emicizumab-kxwh) – Expanded indication

- On October 4, 2018, [Genentech announced](#) the FDA approval of [Hemlibra \(emicizumab-kxwh\)](#), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII (FVIII) inhibitors.
 - Previously, Hemlibra was only approved in adult and pediatric patients with FVIII inhibitors.
- The efficacy of Hemlibra for routine prophylaxis in patients with hemophilia A without FVIII inhibitors was evaluated in two trials, HAVEN 3 and HAVEN 4. HAVEN 3 enrolled 152 adult and adolescent males. HAVEN 4 enrolled 41 adult and adolescent males.
 - In HAVEN 3, patients who received Hemlibra prophylaxis once weekly or every two weeks experienced a 96% (95% CI: 92.5, 98.0; $p < 0.0001$) and 97% (95% CI: 93.4, 98.3; $p < 0.0001$) reduction in annualized bleed rate (ABR) for treated bleeds, respectively, vs. those who received no prophylaxis.
 - In HAVEN-4, Hemlibra prophylaxis every four weeks led to clinically meaningful control of bleeding (ABR 2.6 [95% CI: 1.5, 4.7]) in patients without FVIII inhibitors.
- Hemlibra carries a boxed warning for thrombotic microangiopathy and thromboembolism.
- The recommended loading dose of Hemlibra is 3 mg/kg by subcutaneous (SC) injection once weekly for the first 4 weeks, followed by a maintenance dose of 1.5 mg/kg once a week, 3 mg/kg once every two weeks, or 6 mg/kg every four weeks.
 - The selection of a maintenance dose should be based on healthcare provider preference with consideration of regimens that may increase patient adherence.
 - After proper training in SC injection technique, a patient may self-inject, or the patient's caregiver may administer Hemlibra, if a healthcare provider determines that it is appropriate.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.